Morepen Laboratories Limited · NSE:MOREPENLAB
Morepen Laboratories — Q1 FY2022 Earnings Presentation
35 slides from Morepen Laboratories's earnings presentation, Jul 27, 2021
Slide 1: Exchange filing cover letter for Investors Presentation Q1 FY22
Date: 27/07/2021 To, National Stock Exchange of India Ltd. BSE Limited Exchange Plaza, Bandra Kurla Complex, Floor 25, Phiroze Jeejeebhoy Towers, Bandra (East), Mumbai- 400 051 Dalal Street, Mumbai- 400 001 Symbol: MOREPENLAB Scrip Code: 500288 Subject: Investors Presentation (Q1’FY22) July, 2021 De
Slide 2: Morepen Laboratories Q1'FY22 Earnings Presentation July 2021
MOREPEN LABORATORIES LIMTED Q1'FY22 earnings Presentation - JULY 2021
Slide 3: Disclaimer/ Confidentiality
Disclaimer/ Confidentiality This presentation has been prepared by Morepen Laboratories Limited (“Company”) solely for information purposes without regard to any specific objectives, financial situations or informational needs of any particular person. This presentation contains expressed or implied
Slide 4: Quarterly Highlights
CONSOLIDATED Q1'FY22 performance QUARTERLY HIGHLIGHTS Rs. in crores Rs. in crores Net Revenue EBIDTA 258.97 388.31 27.90 45.43 Profit before Tax 19.55 38.53 Profit after Tax EPS (3M) 19.36 30.47 Rs. 0.43 Rs. 0.68 Q1'FY21 Q1'FY22 Q1'FY21 Q1'FY22 Q1'FY21 Q1'FY22
Slide 5: Morepen starts trial production of Sputnik V in India
Trial samples of 6 batches being sent to Gamelya, Moscow for f r testing. fo Can start commercial production within 4-6 weeks k subject ks b ect to regulatory subj bj r ry clearances. Capacity t to produce upto ty 250 mn doses pa which can be increased to 500mn Morepen starts trial production of dos
Slide 6: Consolidated Quarterly Performance
CONSOLIDATED quarterly performance
Slide 7: Revenue Growth
CONSOLIDATED REVENUE GROWTH Rs. in crores 1,250 1200 1,000 400 863 750 388.31 772 300 610 500 258.97 200 250 100 HIGHEST HIGHESSTT 0 EVER EEV VER GROWTH FY'18 FY'19 FY'20 FY'21 0 GROW WTTH Annual performance Q1'FY21 Q1'FY22 IN IN A QTR QQTTR Q1'FY22 performance
Slide 8: Business Segments
CONSOLIDATED BUSINESS SEGMENTS API BUSINESS MEDICA C L DEVICES CA FORM R ULAT RM A IONS AT OTC OT TC (S ( UBS B IDIA BS IAR IA ARY RY) Y)
Slide 9: Segments Wise Growth
CONSOLIDATED SEGMENTS WISE GROWTH API DIAGNOSTICS FORMULATIONS DR.MOREPEN -OTC 200 150 40 25 189.97 134.46 39.90 150 162.05 20 23.65 100 30 21.69 30.65 15 100 20 50 10 50 46.56 10 5 0 0 Q1'FY21 Q1'FY22 Q1'FY21 Q1'FY22 0 0 Q1'FY21 Q1'FY22 Q1'FY21 Q1'FY22 *Non-Covid Revenue Growth 172%
Slide 10: Segment Wise Breakup
STANDALONE SEGMENT WISE BREAKUP Formulations share FY'21 q1'FY22 11% API 9.90% API 62.0% 52.1 Diagnostic Devices 52.1% % 36.9% Diagnostics 10.8% 26.1% 36.9 revenue split Q1'FY'22 % formulations 0.80% 11.9% 11.0%
Slide 11: API Business
API BUSINESS leadership through quality
Slide 12: API Revenue
api business API REVENUE Rs. in crores 750 683 500 200 474 189.97 413 150 162.06 339 250 100 50 0 FY'18 FY'19 FY'20 FY'21 0 Q1'FY21 Q1'FY22 Annual performance Q1'FY22 performance
Slide 13: Key API Products
api business KEY API PRODUCTS LORATADINE MONTELUKA K ST KA ^16% ^45% A ORV AT RVA RV VAS ASTA TAT ATIN NEW MOLECULES -5% ^110%
Slide 14: POC Medical Devices
POC MEDICAL DEVICES market leadership
Slide 15: POC Revenue
POC medical devices POC REVENUE Rs. in crores 300 287.35 150 200 134.46 168.35 100 139.75 100 103.35 HIGHEST HIGHESSTT 50 46.56 0 EVER EEV VER FY'18 FY'19 FY'20 FY'21 GROWTH GROW WTTH IN IN A QTR QQTTR 0 Q1'FY21 Q1'FY22 Annual performance Q1'FY22 performance
Slide 16: Growth Drivers
poc medical devices GROWTH DRIVERS ^233% ^183% gluco meters BP Monitors ^730% ^2032% nebulisers oximeters oxygen concentrator
Slide 17: Gluco Meter Revenue
POC medical devices GLUCO METER REVENUE Rs. in crores 200 180.46 150 100 119.55 84.68 100 75 92.92 64.81 50 50 25 HIGHEST HIGHESSTT EVER EEV VER 0 FY'18 FY'19 FY'20 FY'21 25.44 GROWTH GROW WTTH IN IN A QTR 0 Annual performance Q1'FY21 Q1'FY22 QQTTR Q1'FY22 performance
Slide 18: Gluco Meter Installed
POC medical devices GLUCO METER INSTALLED 2 1.692 1.5 1 5.65 MILLION 700 MILLION 0.979 meters installed strips sold so far 0.774 0.5 0.622 q1'Fy21 0.62 MILLION q1'Fy22 86 MILLION 0 FY'18 FY'19 FY'20 FY'21 million meter installed
Slide 19: BP Monitor Revenue
POC medical devices BP MONITOR REVENUE Rs. in crores 75 63.02 50 25 20 20.76 25 29.06 26.50 15 21.76 10 7.33 HIGHEST HIGHESSTT EVER EEV VER 0 5 FY'18 FY'19 FY'20 FY'21 0 GROWTH GROW WTTH Annual performance Q1'FY21 Q1'FY22 IN IN A QTR QQTTR Q1'FY22 performance
Slide 20: Other Products
POC medical devices OTHER PRODUCTS Rs. in crores 50 44.87 43.89 40 37.78 30 30 29.01 28.46 20 20 10 10 13.79 0 FY'18 FY'19 FY'20 FY'21 0 Q1'FY21 Q1'FY22 Annual performance Q1'FY22 performance
Slide 21: Formulations
FORMULATIONS brandeD formulations in india
Slide 22: Formulations Revenue
FORMULATIONS FORMULATIONS REVENUE Rs. in crores 200 150 153.17 137.57 40 131.35 39.90 100 110.51 30 30.65 50 20 10 0 FY'18 FY'19 FY'20 FY'21 0 Q1'FY21 Q1'FY22 Annual performance Q1'FY22 performance
Slide 23: Growth Drivers
FORMULATIONS GROWTH DRIVERS ^179% ^91% antibiotics vitamins ^55% ^201% gastro others
Slide 24: OTC & Nutrition
Dr. Morepen® OTC & NUTRITION
Slide 25: Gross Revenue
GROSS REVENUE Rs. in crores 100 85.55 75 64.63 25 50 54.38 22.93 48.89 20 15 25 10 0 5 8.43 FY'18 FY'19 FY'20 FY'21 0 Annual performance Q1'FY21 Q1'FY22 Q1'FY22 performance* *Non-Covid Revenue 172% Growth;Total 9%
Slide 26: Growth Drivers
GROWTH DRIVERS ^259% ^273% OTC products grooming ^85% 110% general health 0nline Sales
Slide 27: Business Segments
BUSINESS SEGMENTS Covid Range 3.1% on line sales Healthcare 33.6% 11% 33% OTC 46.5% Grooming 16.8% OTC grooming business segments q1'FY22
Slide 28: New Online Launches
NEW ONLINE LAUNCHES immune tea pcos powder collagen muscle food sexual wellness iron & ZInc honey Garcinia vitamins COQ-10 Giloy+Tulsi omega-3 stress & sleep slim shake general health Cod Liver Oil Amla juice exclusive online range launched at www.health.drmorepen.com
Slide 29: Brand Portfolio
BRAND PORTFOLIO an established national household brand with extensive reach and trust Rs. in crores 600 504.26 400 200 370.53 Rx 347.31 OTC 12.3% 195.85 20.4% 262,76 150 200 100 91.29 0 50 FY'18 FY'19 FY'20 FY'21 Devices 0 Annual performance 67.3% Q1'FY21 Q1'FY22 FY'21 Q1'FY22 performance
Slide 30: R&D Spend
consolidated R&D SPEND increasing investment in R&D focus on $40 Billion generic market opening up new initiatives including bio-similars, enzymes Rs. in crores Devices 2.9% ANDA 18.7% 6 5.62 4 API 2 2.65 78.4% 0 segment wise spend Q1'FY21 Q1'FY22 246 people* Q1'FY22 SPEND *Includes R&D/ARD/QC team
Slide 31: Financial Highlights & Ratios
FINANCIAL highlights & ratios
Slide 32: Revenue Highlights
CONSOLIDATED REVENUE HIGHLIGHTS Net Revenue Expenditure ebitda interest cash profit 400 400 50 0.3 50 388.31 40 45.43 0.29 300 300 342.88 40 45.22 30 0.2 258.97 0.21 30 200 200 231.07 20 27.90 27.62 20 0.1 100 100 10 10 0 0 0 0 0 Q1'FY21 Q1'FY22 Q1'FY21 Q1'FY22 Q1'FY21 Q1'FY22 Q1'FY21 Q1'FY22 Q1'FY2
Slide 33: Profitability Ratios
CONSOLIDATED PROFITABILITY RATIOS Q1' FY'21 q1'FY22 change EBIDTA 0.90% 10.8% 11.7% profit before tax 2.37% 7.55% 9.92% profit after tax 0.12% 7.84% 7.96%
Slide 34: Profitability Highlights
CONSOLIDATED PROFITABILITY HIGHLIGHTS PROFIT BEFORE TAX PROVISION FOR TAX PROFIT AFTER TAX EPS(RS.) 40 8 40 0.75 38.53 8.06 30 0.68 30 6 30.47 0.5 20 4 20 0.43 19.36 0.25 10 2 10 19.55 0.19 0 0 0 0 Q1'FY21 Q1'FY22 Q1'FY21 Q1'FY22 Q1'FY21 Q1'FY22 Q1'FY21 Q1'FY22 *Diluted EPS- Rs. 0.59
Slide 35: Take Care - Thank You
Take Care thank you
Morepen Laboratories — Q1 FY2022 Earnings Presentation on 6ix